Oruka Therapeutics, Inc.
NASDAQ:ORKA · NASDAQ Global Market
+$0.46 today
Vol 2.99M · Avg 1.55M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ORKA · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$116.3M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.39, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $83.0K +207.4% | $27.0K -75.7% | $111.0K -2.6% | $114.0K +25.3% | $91.0K | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$83.0K -207.4% | -$27.0K +75.7% | -$111.0K +2.6% | -$114.0K -25.3% | -$91.0K | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $100.6M +34.1% | $75.1M +7309.7% | $1.0M -77.3% | $4.5M -67.7% | $13.8M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $21.3M +63.6% | $13.0M +111.2% | $6.2M +17.3% | $5.3M -2.8% | $5.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $122.0M +38.4% | $88.1M +1126.1% | $7.2M -26.1% | $9.7M -49.5% | $19.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $83.0K +207.4% | $27.0K -75.7% | $111.0K -2.6% | $114.0K +25.3% | $91.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$105.3M -28.1% | -$82.2M -1472.9% | -$5.2M +46.7% | -$9.8M +49.0% | -$19.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$122.1M -38.5% | -$88.1M -1107.8% | -$7.3M +25.9% | -$9.8M +49.1% | -$19.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $16.6M +183.6% | $5.9M +199.6% | $2.0M +189.9% | $675.0K | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 -100.0% | $1.5M | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $16.6M +277.8% | $4.4M +124.8% | $2.0M +2402.4% | -$85.0K -753.8% | $13.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$105.4M -25.9% | -$83.7M -1468.2% | -$5.3M +46.2% | -$9.9M +48.6% | -$19.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$105.4M -25.9% | -$83.7M -1468.2% | -$5.3M +46.2% | -$9.9M +48.6% | -$19.3M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 +53.7% | -$5 -12.4% | -$4 +46.3% | -$8 +50.4% | -$17 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 +53.7% | -$5 -12.4% | -$4 +46.3% | -$8 +50.4% | -$17 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $45.6M +171.7% | $16.8M +16.5% | $14.4M +0.0% | $14.4M +3.6% | $13.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $45.6M +171.7% | $16.8M +16.5% | $14.4M +0.0% | $14.4M +3.6% | $13.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
AnaptysBio, Inc.
NASDAQ:ANAB
$2.40B
Kodiak Sciences Inc.
NASDAQ:KOD
$1.91B
UroGen Pharma Ltd.
NASDAQ:URGN
$1.60B
Mind Medicine (MindMed) Inc.
MNMD
$1.56B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.49B
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
$1.35B
Xencor, Inc.
NASDAQ:XNCR
$937.70M
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$858.23M
Oculis Holding AG
NASDAQ:OCS
$642.01M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$605.61M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ORKA generate?
Oruka Therapeutics, Inc. (ORKA) reported $0.00 of revenue in fiscal 2025.
Is ORKA profitable?
Oruka Therapeutics, Inc. (ORKA) reported -$105,433,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.